Treatments for stroke prevention in atrial brillation: a network meta-analysis and indirect comparisons versus dab- igatran etexilate. Thromb Haemost. 2010;104(6):1106-1115. 89. Label approved on 03/04/2011 for Pradaxa, NDA no. 022512. In: United States Food and Drug Administration; 2010. 90. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate a novel, reversible, oral direct thrombin inhibitor: interpre- tation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116-1127. 91. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic 60. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial brillation after transient ischaemic attack or minor stroke. Lancet. 1993;342(8882):1255-1262. 61. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagu- lants vs aspirin in nonvalvular atrial brillation: an individual patient meta-analysis. JAMA. 2002;288(19):2441-2448 62. Benavente O, Hart R, Koudstaal P, Laupacis A, McBride R. Antiplatelet therapy for preventing stroke in patients with atrial brillation and no previous history of stroke or transient ischemic attacks. In: Warlow C, Van Gijn J, Sandercock P, eds. Stroke Module of the Cochrane Database of Systematic Reviews. Oxford, England: The Cochrane Collaboration; 1999. 63. Posada IS, Barriales V; LASAF Pilot Study Group. Alternate- day dosing of aspirin in atrial brillation. Am Heart J. 1999; 138(1 pt 1):137-143. 64. Sato H, Ishikawa K, Kitabatake A, et al; Japan Atrial Fibril- lation Stroke Trial Group. Low-dose aspirin for preven- tion of stroke in low-risk patients with atrial brillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2006;37(2): 447-451. 65. Diener HC, Lowenthal A. Antiplatelet therapy to prevent stroke: risk of brain hemorrhage and ef cacy in atrial bril- lation. J Neurol Sci. 1997;153(1):112. 66. 